The latest update is part of broader goals to create the industry's first unified digital data platform for decentralized and hybrid testing.
ROCKVILLE, Md., Sept. 27, 2023/PRNewswire/ -- Emmes, a full-service global contract research organization (CRO) dedicated to supporting the advancement of public health and biopharmaceutical innovation, announces the addition of capabilities from telehealth within Advantage eClinical. The new app means any scheduled visit can become virtual with augmented video calls directly through the platform and patients logging in through their existing participant portal. Advantage eClinical is designed to enable a simple, intuitive experience that fits seamlessly into the daily lives of participants and study sites.
The addition of telehealth capabilities is part of a much broader development plan for Emmes' third-generation clinical data platform. The company's vision is to create the first unified, flexible digital testing infrastructure that minimizes disruption to sites and participants and is more accessible. Our unique, flexible platform adapts to all trial modalities (traditional, decentralized, including hybrid and fully virtual), as well as the needs of patients, sponsors and sites. It also includes all tasks from data capture, cleaning and monitoring to workflow management, sample tracking and even clinical assessment and engagement tools.
"What we are building with Advantage eClinical is more than an EDC or eCOA/ePRO. It is a platform to accelerate the delivery of all types of trial designs through a unified modular system. 90% of respondents in the Study Insights and Ideas from the Information and Study Center on Clinical Research Participation (CISCRP) 2021 emphasizes the importance of having options for completing study visits, such as virtual and home visits. By eliminating the need for sponsors to purchase and establish systems of additional points decentralized trials (DCTs), I hope that more studies will offer patient-centered options for participation," said Ching Tian, chief innovation officer at Emmes.
Ashley Davidson, associate vice president of operations and product management at Emmes explained that the telehealth app greatly simplifies workflow for site staff because all information is on the screen at once, including assessment forms and records. from the patients. He added: "It gives that real-world feel of an in-person visit and allows for simultaneous note-taking and record-checking. On a more practical level, operating a decentralized or hybrid testing design means we can also open up testing to more diverse groups of participants, which has been a great push by regulators.
Advantage eClinical is cloud-based and 21 CFR Part 11, GDPR, and HIPAA compliant. It is available as a standalone product (software as a service (SaaS)) to any biopharmaceutical and CRO customer, and has supported more than 1,000 trials, for almost a million patients in more than 70 countries, spanning more than 31,000 clinical trial sites.
About EmmesFounded more than 45 years ago, Emmes is a full-service global clinical research organization dedicated to excellence in supporting the advancement of public health and biopharmaceutical innovation. The company's clients include numerous US federal government agencies and institutes and a broad range of biotechnology, pharmaceutical and medical device companies around the world. To learn more about how our research is having a positive impact on human health, visit the Emmes website at www.emmes.com.
Logo - https://mma.prnewswire.com/media/220594/Emmes_Logo.jpg
View original content: https://www.prnewswire.com/news-releases/emmes-introduce-capacidades-de-telesalud-en-advantage-eclinical-301940742.html
